COMPASS Pathways

Companies and investors have been pouring more money into the psychedelic therapy space in recent years, inspired by the growing success of Johnson & Johnson’s Spravato (esketamine), which is deri

Atai Life Sciences of Germany’s proposed acquisition of private UK firm Beckley Psytech to create a psychedelic mental health powerhouse at a time when US regulators and politicians are sending encour

British science is often held up as a shining light: both a source of national pride thanks to the country’s huge contributions in the past, and a crucial part of the economy which should help drive g

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a